Treatment options for the management of chronic obstructive pulmonary disease

Formulary

Volumn 39, Issue 11, 2004, Pages 542-555

  Roefaro, John ^a   Daryanani, Anita A ^a  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DELTACORT; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEVALBUTEROL; LONG ACTING DRUG; ORCIPRENALINE; PHOSPHODIESTERASE INHIBITOR; PIRBUTEROL ACETATE; PLACEBO; PREDNISOLONE; SALBUTAMOL; SALMETEROL XINAFOATE; SHORT ACTING DRUG; THEOPHYLLINE DERIVATIVE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; MEDICAL DECISION MAKING; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION; VACCINATION;

EID: 9244221606     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Executive Summary Update of the NHLBI/WHO Workshop Report - Global Strategy for Diagnosis, Management, and Prevention of COPD. November 2003. Available at: http://www.goldcopd.com/revised_es.pdf. Accessed October 29, 2004.
2. American Thoracic Society and the European Respiratory Society. Standards for the Diagnosis and Management of Patients with COPD. Available at: http://www.thoracic.org/copd/. Accessed October 29, 2004.
3. National Heart, Lung, and Blood Institute. Morbidity & Mortality: Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD; US Department of Health and Human Services; Public Health Service, National Institutes of Health, 2004. Available at: http://www.nhlbi.nih.gov/ resources/docs/cht-book.htm.
4. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax. 2004;59(suppl 1):1-232.
5. Konzem SL, Stratton MA. Chronic Obstructive Lung Disease. In: DiPiro JT, Talbert RT, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach, 5th ed. New York, NY: McGraw-Hill; 2002;511-529.
6. Barnes PJ, Chronic obstructive pulmonary disease. NEJM. 2000;343:269-280.
7. Hayes GB, Christiani DC. Measures of small airways disease as predictors of chronic obstructive pulmonary disease. Occup Med. 1993;8:375-395.
8. Anthonisen NR, Connett JE, Altose MD, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497-1505.
9. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA. 1982;248:1465-1477.
10. Fiore MC. Treating Tobacco Use and Dependence. Available at: http://www.surgeongeneral.gov/tobacco/smokesum.htm. Accessed October 29, 2004.
11. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272:1661-1665.
12. Nichol KL, Nordin J, Mullooly J, Lask R, Filibrandt K, Iwane M. Influenza vaccination and reduction in hospitalizauons for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322-1332.
13. Datta D, Vitale A, Lahiri B, ZuWallack R. An evaluation of nebulized levalbuterol in stable COPD. Chest. 2003;124:844-849.
14. Cook D, Guyatt G, Wong E, Goldstein R, et al. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:85-90.
15. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994;7:103-107.
16. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med. 1995;89:357-362.
17. Celik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. Respiration. 1999;66:434-439.
18. Serevent [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2003.
19. Maconochie JG, Minton NA, Chilton JE, Keene ON. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Br J Clin Pharmacol. 1994;37:199-204.
20. Gross NJ. Ipratropium bromide. NEJM. 1988;319:486-494.
21. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest. 1994;105:1411-1419.
22. Jeffery SM. Tiotropium: a novel anticholinergic for the once-daily treatment of COPD. Formulary. 2004;39:203-212.
23. Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr, and the US Tiotropium Study Group. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest. 2000;118:1294-1302.
24. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
25. Vincken W, van Noord JA, Greefhorst AP, et al, and the Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19:209-216.
26. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47-55.
27. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med. 2003;97:1014-1020.
28. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125:249-259.
29. Zu Wallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001;119:1661-1670.
30. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819-1823.
31. Pauwels RA, Lofdahl CG, Laitinen LA, et al, and the European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 1999;340:1948-1953.
32. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297-1303.
33. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902-1909.
34. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124:834-843.
35. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 1991;114:216-223.
36. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001;297:267-279.
37. Norman P. PDE4 inhibitors 2001. Patent and literature activity 2000-September 2001. Expert Opin Ther Pat. 2002;12:93-112.
38. Compton CH, Gubb J, Nieman R, and the International Study Group. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet. 2001;358:265-270.
39. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 12th ed. Hudson, OH: Lexi-Comp, Inc; 2004.
40. National Drug Data File [database online]. Blue Book Average Wholesale Price. San Bruno, California: FirstData Bank; 2004. Available at: http://www.firstdatabank.com/. Accessed October 21, 2004.